A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Part A of the study will evaluate the safety and tolerability of BP2202 and determine recommended phase 2 dose. Part B of the study will further evaluate safety and explore the potential anti-myeloma activity of BP2202 at recommended phase 2 dose.

Inclusion Criteria:

• Diagnosis of Multiple Myeloma with relapsed or refractory disease.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Adequate organ function.
• Have measurable disease

Exclusion Criteria:

• Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.
• Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.